ENTR-601-44 is named as a drug or biological intervention in 2 clinical trials in our UK trial register, 1 of which is recruiting. The lead sponsor is Entrada Therapeutics, Inc.. Registered phases: Phase 1/2 and Phase 2. Conditions studied include Duchenne Muscular Dystrophy (DMD).
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07037862 | A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44 (ClinicalTrials.gov ↗) Duchenne Muscular Dystrophy (DMD) |
Phase 1/2 | Recruiting |
| NCT07682129 | Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Evaluate the Safety and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE) (ClinicalTrials.gov ↗) Duchenne Muscular Dystrophy (DMD) |
Phase 2 | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Duchenne Muscular Dystrophy (DMD) | 2 |
| Lead sponsor | Trials |
|---|---|
| Entrada Therapeutics, Inc. | 2 |
| Register | ENTR-601-44 trials |
|---|---|
| Clinical trials in UK | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how ENTR-601-44 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists ENTR-601-44 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.